🔗 Share this article

Given that the United States continues making sweeping adjustments to its immunization schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning coronavirus vaccinations during the pandemic and has focused upon possible fatalities following Covid vaccination in her recent time at the FDA.

Proposed Changes to Childhood Vaccine Program

Health officials had intended to reveal sweeping changes to the childhood immunization program in December, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of step with much of the international standard with no evidence for public health gain. The planned update has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for halting specific childhood vaccine recommendations in the US to become more in line with Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

To date comments, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious track record in medication creation, regulation or management, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the CDER, stated Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a major agency. She is not an expert in drug approvals.”

Previous heads of the center would “grasp legal statutes and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

CDER has an enormous portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those need to be supervised,” Dr. Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the position, which oversees in excess of 5,000 personnel. “It’s a massive management job, if you perform it correctly,” she concluded.

Response and Controversial Initiatives

Regarding inquiries about Høeg’s qualifications and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a press secretary responded that the “questions rely on inaccurate presumptions”.

“This background matches the responsibilities of her position,” the official said, citing the time Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's new expedited review system, a contentious expedited medication authorization process that apparently concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent rules of all drugs, aside from immunizations.”

Documented Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, past, critics observe. She released a analysis using non-validated public submissions to assess the frequency of myocarditis following COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the current federal leadership encompassed changing rules for novel immunizations and discontinuing “optional” immunizations, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of barring young men from receiving COVID-19 vaccines.

“She’s an complete ideologue who commences with her beliefs and tailors the evidence to accommodate the science in a very misleading, fraudulent fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|